Articles tagged "Immunosuppression"

2019 American Transplant Congress
MDSCs Prolong Allogeneic Cardiac Graft Survival by Regulating Interferon Type 1 Signaling
S. Cai¹, P. T. Sage¹, T. J. Borges¹, T. Ichimura¹, S. K. Eskandari¹, J. Y. Choi¹, I. Salkuj¹, B. S. AI Dulaijan¹, H. Allos¹, J. Miao², L. V. Riella¹, A. K. Chandraker¹, J. R. Azzi¹
¹Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Boston Children's Hospital, Harvard Medical School, Boston, MA
*Purpose: We previously demonstrated that donor-derived regulatory dendritic cells (DCreg), contrary to recipient derived DCreg, promote antigen-specific allograft protection. As myeloid-derived suppressor cells (MDSC) show…
2019 American Transplant Congress
Implementation of a De Novo Belatacept Protocol
D. Wojciechowski¹, M. Jacobs², K. Safa¹, H. Gilligan¹, H. Eliot¹, W. W. Williams, Jr¹
¹Massachusetts General Hospital, Boston, MA, ²Wake Forest, Winston-Salem, NC
*Purpose: The use of belatacept with basiliximab induction and maintenance MMF/prednisone when compared to cyclosporine is associated with superior long-term patient and graft survival but…
2019 American Transplant Congress
Belatacept Use in High Kidney Donor Profile Index Kidney Transplant Recipients
D. Britt¹, A. Gharabagi¹, K. Botkin¹, T. Horwedel², C. Carthon¹, J. Hagopian¹
¹Pharmacy, Barnes-Jewish Hospital, St. Louis, MO, ²Veloxis Pharmaceuticals, Cary, NC
*Purpose: To determine whether the use of belatacept is associated with renal function preservation in kidney transplant recipients from donors with a kidney donor profile…
2019 American Transplant Congress
ICOS⁺PD-1⁺ Circulating T Follicular Helper Cells Are a Biomarker of Humoral Alloreactivity and Predict Donor-Specific Antibody Generation Following Transplantation
G. M. La Muraglia II, M. E. Wagener, M. L. Ford, I. R. Badell
Emory Transplant Center, Atlanta, GA
*Purpose: Mounting evidence in kidney transplantation suggests that donor-specific antibodies (DSA) significantly contribute to renal allograft loss. However, biomarkers to guide clinical management of DSA…
2019 American Transplant Congress
Anti-Complement Component 5 Antibody Based Immunosuppression Induced Accommodation in ABO Incompatible Heart Transplantation
S. Park¹, S. Lee¹, J. Hwang¹, J. Ryu², T. Koo², C. Ahn³, J. Yang⁴
¹Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea, Republic of, ²Transplantation Center, Seoul National University Hospital, Seoul, Korea, Republic of, ³Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of, ⁴Department of Surgery, Seoul National University Hospital, Seoul, Korea, Republic of
*Purpose: Plasmapheresis in combination with immunoglobulin and rituximab is often used to induce accommodation in ABO-incompatible (ABOi) living-donor transplantation; however, this regimen cannot be applied…
2019 American Transplant Congress
Racial Disparities in Documentation of Non-Adherence and Its Relation to Rejection in Pediatric Kidney Transplant Recipients
T. Melanson, J. Hogan, K. Maroney, R. Patzer, R. George
Emory University, Atlanta, GA
*Purpose: Black patients have historically been disadvantaged throughout the transplant process. Many factors impact the success of kidney transplantation, but the need for strict adherence…
2019 American Transplant Congress
Assessing the Effectiveness of Early Maintenance Immunosuppression Practices in Liver Transplantation
T. Bittermann, R. Hubbard, J. Lewis, D. Goldberg
University of Pennsylvania, Philadelphia, PA
*Purpose: Evidence regarding the efficacy of maintenance immunosuppression (IS) regimens for liver transplantation (LT) arise from clinical trials. However, the ‘real world’ effectiveness of such…
2019 American Transplant Congress
Determining the Role of Insurance Coverage at the Time of Renal Transplantation as a Predictor of Medication Misadventure
D. Wilkerson, P. Klem
Pharmacy, University of Colorado Skaggs School of Pharmacy, Aurora, CO
*Purpose: To determine if patients who receive financial assistance through the American Kidney Fund (AKF) for health care premiums at the time of transplant are…
2019 American Transplant Congress
Impact Of Selective Cd28 Blockade On Protective Immunity To A Murine Epstein-Barr Virus Homolog
R. L. Crepeau, J. A. Elengickal, M. L. Ford
Surgery, Emory University, ATLANTA, GA
*Purpose: CTLA-4Ig blocks CD80/CD86, the ligands for both CD28 and CTLA-4. Thus, in addition to the intended effect of blocking CD28-mediated costimulation, CTLA4-Ig also has…
2019 American Transplant Congress
Infectious Complications in Tocilizumab-Treated Kidney Transplant Recipients
S. Sethi, A. Peng, R. Najjar, A. Vo, S. Jordan, E. Huang
Cedars Sinai Medical Center, Los Angeles, CA
*Purpose: Tocilizumab blocks IL-6 signaling, inhibiting maturation of B cells to plasma cells and antibody production. We have used tocilizumab since 2012 to treat kidney…